explore -WSS

explore

author：fashion 2025-09-27 21:27:14 - browse：6327

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Biden’s NIH nominee is languishing in Congress

WSS

Recent heat wave in the Mediterranean caused by climate change: Study

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

Biden declares emergency in flood

Severe heat forecast: Where scorching temperatures will persist over the next week

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medical records are filled with copy

How a key Senate committee is planning to regulate PBMs

Medical leaders decry Supreme Court decision on affirmative action

What Henrietta Lacks's story taught me about my role as a doctor

Novavax promises a turnaround & Lilly roils the obesity market

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Sports medicine is finally prioritizing gender equality

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Jerome Adams on the need for new antivirals for Covid

Burning questions about Delta and the next phase of the Covid pandemic

hotspot

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Biden’s NIH nominee is languishing in Congress

Clinic falsely told dozens they had Alzheimer's, suits say

Where does female orgasm come from? Scientists think they know

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

White House announces new plan to address the growing threat of xylazine in overdose crisis

knowledge

hotspot

explore

leisure time